Agenda

  1. Home
  2. Agenda

2026 Symposium Chairs

Honorary Chair: Arno J. Mundt, MD, FACRO, FASTRO, Distinguished Professor and Chair, Radiation Medicine & Applied Sciences, Member, Executive Governing Committee, Moores Cancer Center, UC San Diego
Committee Chair: Ida Deichaite, PhD, Assistant Professor, Department of Radiation Medicine and Applied Sciences, Center for Precision Radiation Medicine, UC San Diego
Committee Co-Chair: Andrew Sharabi, MD, PhD, Associate Professor, Director, Center for Precision Radiation Medicine, Jacobs Chancellor’s Endowed Chair, Director, Moores Cancer Center Radiation Medicine Core Facility, Radiation Medicine and Applied Sciences, UC San Diego

2026 Symposium Committee

Phil Chamberlain, DPhil, Co-Founder, President, and CEO, Neomorph
Christine Chung, MD, Professor and Chair, Director MSK Imaging Research Group, Department of Radiology, UC San Diego
Ezra Cohen, MD, Chief Medical Officer, Oncology, Tempus
J. Silvio Gutkind, PhD, Chair and Professor, Department of Pharmacology, Moores Cancer Center, UC San Diego
Jake Haling, PhD, Head of Oncology Drug Discovery, San Diego, Novartis Institutes for Biomedical Research
Hunter Reed, MBA, Senior Vice President, Strategic Marketing Director, Alexandria Venture Investments, Alexandria Real Estate Equities, Inc.
Nicole Steinmetz, PhD, Vice Chair, Department of NanoEngineering, Center for Nano-ImmunoEngineering, Center for Engineering in Cancer, Moores Cancer Center, Center for Precision Immunotherapy, UC San Diego

2026 Agenda

Welcome Remarks
Arno J. Mundt, FACRO, FASTRO, Distinguished Professor and Chair, Radiation Medicine & Applied Sciences, Member, Executive Governing Committee, Moores Cancer Center, UC San Diego
Ida Deichaite, PhD, Assistant Professor, Department of Radiation Medicine and Applied Sciences, Center for Precision Radiation Medicine, UC San Diego
Fireside Chat
Moderator: Laura Shawver, PhD, Venture Partner at Raven (RA Ventures)
John Reed, MD, PhD, Executive Vice President, Innovative Medicine, R&D, Executive Committee Member, Johnson & Johnson
Featured Talk
Introduction by: Hunter Reed, MBA, Senior Vice President, Strategic Market Director & Alexandria Venture Investments at Alexandria Real Estate Equities, Inc.
The Golden Years of Biotech – How Long Will They Last?
Josh Schimmer, MD, Biotech Equity Research Analyst, Cantor Fitzgerald and Co.
Developments in KRAS
Session Chairs: James Christensen, PhD, President, Head of Research & Development, Terremoto Biosciences; Jake Haling, PhD, Head of Oncology Drug Discovery, San Diego, Novartis Institutes for Biomedical Research
Duane Roth Achievement Award Lecture
Old Targets, New Tricks: FTIs and Menin Inhibitors as Precision Combination Agents
Troy Wilson, PhD, JD, President, CEO and Chairman, Kura Oncology
Targeting Oncogenic RAS with Tri-Complex RAS(ON) Inhibitors
Elena Koltun, PhD, SVP, Medicinal Chemistry, Revolution Medicines
Clinical update on KRAS inhibitors in NSCLC
Lyudmila Bazhenova, MD, Clinical Professor, Division of Medical Oncology, Department of Medicine, Director, Hematology Oncology Training Program, Moores Cancer Center, UC San Diego
Session - Immunotherapy
Session Chairs: Ezra Cohen, MD, Chief Medical Officer, Oncology, Tempus; Asona Lui, MD, PhD, Assistant Professor, Division of Radiation Oncology, Radiation Medicine & Applied Sciences, Center for Precision Radiation Medicine, UC San Diego
Discovery and optimization of NEO-811, a first-in-class molecular glue degrader of ARNT, utilizing structure-based drug design
Jennifer Griffin, PhD, Principal Scientist, Neomorph
New frontiers in immunotherapy - the development of a PD1xVEGFxIL2 trispecific immune checkpoint inhibitor
Fredrik Wiklund, CEO, Bright Peak Therapeutics
Plants as bioreactors for next-gen immune-oncology products: from canine cancer trials to space missions
Nicole Steinmetz, PhD, Vice Chair, Department of NanoEngineering, Center for Nano-ImmunoEngineering, Center for Engineering in Cancer, Moores Cancer Center, Center for Precision Immunotherapy, UC San Diego
Longitudinal Methylation ctDNA Predicts Immunotherapy Progression Across Solid Tumors
David Tsao, PhD, Co-Founder, and CTO, BillionToOne
Irreversible Electroporation: Combining Tumor Ablation with Potential for Intratumoral Drug Delivery
Rebekah White, MD, FACS, Professor of Surgery, Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, UC San Diego
INBRX-106 first clinical validation of OX40 agonist induced costimulation in a randomized clinical study
Mark Lappe, PhD, Founder and CEO, Inhibrx
Session - AI
Session Chair: Paul Rejto, PhD, Vice President, Discovery Technologies, Pfizer
Beyond Multiomics
Michael Goldberg, PhD, Vice President, R&D, BostonGene Corporation
Building a virtual cancer patient: Multimodal AI for Precision Oncology
Erik Bergstrom, PhD, Machine Learning, Natera
AI-Guided Discovery of IAM1363: A Clinical-Stage, Next-Generation HER2 Type II Inhibitor with High Selectivity and Brain Penetrance
Laurent Gomez, PhD, Senior Vice President, Head of Discovery, Iambic Therapeutics
Targeting the Untouchable: MYC, DNA Repair, and Next-Gen Therapeutic Platforms
Session Chair: Sandip Patel, MD, Professor of Medicine, Deputy Director, Sanford Stem Cell Clinical Center, Moores Cancer Center, UC San Diego
Enlaza’s War-Lock Platform: Introducing Covalency into Protein Therapeutics
Danny Beck, Vice President, Business Development, Enlaza Therapeutics
Exploiting the Achilles Heel of Historically Undruggable MYC through Small Molecule Mediated Context-Dependent Translation Inhibition
Lawrence Hamann, PhD, Co-Founder, President, and CEO, Interdict Bio
Discovery of PARG Inhibitor ETX-19477
Jeffrey Stafford, PhD, President and CEO, 858 Therapeutics
Fluorescent Biosensors for Oncogenic Activity Tracking and Live Cell Pharmacology
Jin Zhang, PhD, Vice Chair and Professor, Department of Pharmacology, Moores Cancer Center, UC San Diego
Session - Radiopharmaceuticals in Precision Oncology: Imaging, Theranostics, and Combination Strategies
Session Chairs: Christine B. Chung, MD, Professor and Chair, Director MSK Imaging Research Group, Department of Radiology, UC San Diego; Todd A. Pawlicki, PhD, FAAPM, FASTRO, Professor and Vice Chair for Medical Physics, Director, Division of Medical Physics, Department of Radiation Medicine and Applied Sciences, UC San Diego
The landscape of opportunities for combining theranostics and radiotherapy in prostate cancer
Tyler Seibert, MD, PhD, Associate Professor, Division of Radiation Oncology, Co-Director of the UC San Diego Center for Translational Imaging (CTI), Departments of Radiation Medicine and Applied Sciences; Urology; Radiology; and Bioengineering, Moores Cancer Center, UC San Diego
Women’s Cancer Imaging
Rebecca Rakow-Penner, MD, PhD, Associate Professor, Department of Radiology, Department of Bioengineering, Co-Director for the Center for Translational Imaging, UC San Diego
Clinical Translation of Dosimetry-Guided Theranostics with anti-PD-1/L1 Checkpoint Inhibitors
Evan Sengbusch, PhD CEO, Director, and Board Member, Archeus Technologies
Next generation radiopharmaceuticals in advanced prostate cancer
Zhengtao Qin, PhD, US Medical Lead, Prostate Cancer, AstraZeneca
Closing Remarks
Andrew Sharabi, MD, PhD, Associate Professor, Director, Center for Precision Radiation Medicine, Jacobs Chancellor’s Endowed Chair, Director, Moores Cancer Center Radiation Medicine Core Facility, Radiation Medicine and Applied Sciences, UC San Diego

Archived Agendas

The success of the Symposium is made possible by our dynamic sessions featuring distinguished leaders from industry and academia.

View Past Agendas: 2025 Agenda (PDF) | 2024 Agenda (PDF) | 2023 Agenda (PDF)

2022 Agenda (PDF) | 2021 Agenda (PDF) | 2020 Agenda (PDF) | 2019 Agenda (PDF)